Valuation
- Market cap
- 221,162,000
- Revenue TTM
- $25,420,000
- Net income TTM
- $-143,750,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -565.50%
- Debt to equity
- 0.00
Trading
- Volume
- 463,700
- Avg volume
- 338,868
- Day's range
- $5.17 – $6.22
- Shares out
- 38,937,000
- Stochastic %K
- 12%
- Beta
- -0.24
- Analysts
- Strong Sell
- Price target
- $17.00
Company profile
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neur...
Show more
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 857 520 9158
- Website
- https://www.entradatx.com
- Address
- One Design Center Place, Suite 17- 500, Boston, United States
Latest news
No headlines yet.
